SCHEMBL20313571

SCHEMBL20313571

C=C(CO)C(=O)OCCOc1cc(OCCOC(=O)C(=C)CO)cc(-c2ccc(-c3ccc(CCCCF)cc3)cc2CC)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 7/20 0.35
▸ RARB P10826 5/20 0.33
▸ RARA P10276 2/20 0.33
▸ RARG P13631 1/20 0.33
▸ FFAR1 O14842 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ SLCO1B3 Q9NPD5 1/20 0.32
▸ SLCO1B1 Q9Y6L6 1/20 0.32
▸ CSF3R Q99062 1/20 0.32
▸ SLC13A5 Q86YT5 1/20 0.32
▸ PTPN11 Q06124 1/20 0.32
▸ LTB4R Q15722 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20313572 0.97 FFAR4 (0.36) FFAR4RARBRARARARGFFAR1
SCHEMBL20313575 0.93 FFAR4 (0.35) FFAR4RARBRARARARGFFAR1
SCHEMBL20313562 0.92 MEN1 (0.41) RARBRARARARGMEN1USP2
SCHEMBL20313576 0.90 FFAR4 (0.36) FFAR4RARBRARARARGFFAR1
SCHEMBL19855548 0.90 MEN1 (0.41) RARBRARARARGMEN1USP2
SCHEMBL19855960 0.89 FFAR4 (0.34) FFAR4RARBRARARARGMEN1
SCHEMBL20313580 0.89 RARB (0.34) FFAR4RARBRARARARGMEN1
SCHEMBL20313564 0.89 MEN1 (0.42) RARBRARARARGMEN1USP2
SCHEMBL19722033 0.87 MEN1 (0.46) FFAR4RARBRARARARGMEN1
SCHEMBL19855947 0.86 FFAR4 (0.34) FFAR4RARBRARARARGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
EP-3351525-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2018-07-25 — — EP disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 — — US disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE C1S, CCND1, C5 FFAR4 1865/4885RARB 3791/4885RARA 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback